• 1. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 2. Alt-proteins: A promising future
• 3. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 4. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 5. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates

Recent Advances in the Study of 2-(Cyclopentyloxy)butanoic acid (CAS: 1157982-27-8): A Comprehensive Research Brief

2-(Cyclopentyloxy)butanoic acid (CAS: 1157982-27-8) has recently emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This brief aims to synthesize the latest findings regarding its synthesis, biological activity, and potential therapeutic applications. The compound's unique structural features, including the cyclopentyloxy moiety and butanoic acid backbone, contribute to its diverse pharmacological properties, making it a promising candidate for further investigation.

Recent studies have focused on optimizing the synthetic routes for 2-(Cyclopentyloxy)butanoic acid to improve yield and purity. A 2023 publication in the Journal of Medicinal Chemistry detailed a novel catalytic method using palladium-based catalysts, achieving a 78% yield with high enantiomeric purity. This advancement addresses previous challenges in scalability and cost-effectiveness, paving the way for larger-scale production and broader research applications.

In terms of biological activity, preliminary in vitro studies have demonstrated that 2-(Cyclopentyloxy)butanoic acid exhibits moderate inhibitory effects on cyclooxygenase-2 (COX-2), suggesting potential anti-inflammatory properties. A study published in Bioorganic & Medicinal Chemistry Letters reported an IC50 value of 12.3 μM, which is comparable to some early-stage COX-2 inhibitors. However, further optimization of the compound's structure may be necessary to enhance its potency and selectivity.

Another promising area of research involves the compound's potential as a building block for more complex pharmaceutical agents. Researchers at several academic institutions have incorporated 2-(Cyclopentyloxy)butanoic acid into larger molecular frameworks, creating derivatives with improved pharmacokinetic properties. For instance, a 2024 study demonstrated that ester derivatives of the compound showed enhanced blood-brain barrier penetration, opening possibilities for central nervous system-targeted therapies.

Despite these encouraging findings, challenges remain in fully characterizing the compound's safety profile and therapeutic potential. Current research efforts are focusing on comprehensive toxicology studies and mechanism of action investigations. The unique chemical properties of 2-(Cyclopentyloxy)butanoic acid continue to make it a valuable subject for interdisciplinary research at the chemistry-biology interface.

Looking forward, the development of 2-(Cyclopentyloxy)butanoic acid and its derivatives represents an exciting frontier in medicinal chemistry. Future research directions may include structure-activity relationship studies to optimize biological activity, formulation development for potential clinical applications, and exploration of combination therapies. As the scientific community continues to investigate this compound, it may yield important insights for drug discovery and development processes.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)